ストックスクリーナーアプリを入手
141.86
3.29%
4.52
アフターアワーズ：
141.86
前日終値:
$137.34
開ける：
$141.81
24時間の取引高:
809.19K
Relative Volume:
1.24
時価総額：
$9.18B
収益：
$74.06M
当期純損益:
$-114.71M
株価収益率:
-78.64
EPS:
-1.8039
ネットキャッシュフロー:
$-117.90M
1週間 パフォーマンス:
-0.80%
1か月 パフォーマンス:
-5.80%
6か月 パフォーマンス:
+36.00%
1年 パフォーマンス:
+119.26%
1日の値動き範囲:
$138.23
$143.45
1週間の範囲:
$134.10
$147.71
52週間の値動き範囲:
$62.24
$160.81
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
141.86 | 9.18B | 74.06M | -114.71M | -117.90M | -1.8039 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-10 | アップグレード | Goldman | Neutral → Buy |
| 2026-05-21 | 開始されました | Wolfe Research | Outperform |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-12 | 開始されました | Leerink Partners | Outperform |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency - Montgomery Advertiser
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap UpWhat's Next? - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock forecasts - Yahoo Finance UK
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) stock price, news, quote and history - uk.finance.yahoo.com
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup - ChartMill
How Protagonist Therapeutics Inc. (PTGX) Affects Rotational Strategy Timing - Stock Traders Daily
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 20% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Takeda wins FDA approval for MIMRYLO, triggers $275m payout to Protagonist - scanx.trade
Protagonist Therapeutics stock holds near 52-week high as investors digest recent earnings - ad-hoc-news.de
Protagonist Therapeutics stock gains as Bank of America builds a sizable stake - ad-hoc-news.de
1,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup - ChartMill
California State Teachers Retirement System Acquires 284 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 11,200 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics CEO sells $18.2m in shares By Investing.com - Investing.com Australia
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Dinesh Ph Patel Sells 63,548 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 54,174 Shares - MarketBeat
Protagonist Therapeutics CEO sells $18.2m in shares - Investing.com India
Protagonist Therapeutics (PTGX) CEO sells 125K shares in preset plan - Stock Titan
Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock - Moomoo
Protagonist Therapeutics at Cantor conference: cash, launches and pipeline By Investing.com - Investing.com Nigeria
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $1,048,759.80 in Stock - MarketBeat
Protagonist Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript - GuruFocus
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Protagonist Therapeutics CEO highlights strong drug approvals and steady biotech progress in 2026. - pluang.com
Protagonist Therapeutics authorizes $300 million buyback plan By Investing.com - Investing.com Nigeria
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
Protagonist Therapeutics authorizes $300 million buyback plan - investing.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
Up to $300 million could go toward buying back shares at Protagonist Therapeutics. - Stock Titan
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status - Yahoo Finance
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? - Yahoo Finance
Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run - simplywall.st
Research Analysts Offer Predictions for PTGX Q1 Earnings - marketbeat.com
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 - ACCESS Newswire
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News - Yahoo Finance
Protagonist Therapeutics (NASDAQ:PTGX) Gets A Higher Price Target - Kalkine Media
BMO raises Protagonist Therapeutics price target on Mimrylo approval By Investing.com - Investing.com Canada
PTGX Maintained by BMO Capital -- Price Target Raised to $190 - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $190.00 Price Target at BMO Capital Markets - MarketBeat
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call - Yahoo Finance
Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval? - Yahoo Finance
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):